Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Akron BioProducts LLC is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners, ensuring that no single examiner is responsible for the company's entire current workload. Furthermore, the portfolio is spread across 2 distinct art units, reflecting a range of technical classifications within their biotechnology filings.
ABBAS, SYED JARAR serves as the busiest examiner for the portfolio, holding 1 pending action. This figure matches the workload of the other examiner, as the 2 pending actions are split evenly between the 2 distinct examiners. The presence of 2 distinct art units suggests that the company's intellectual property strategy involves different biological or pharmaceutical sub-categories, requiring the legal team to adapt to the specific standards of 2 different administrative groups. This distribution means that the outcome of the 2 pending actions will depend on the unique perspectives of 2 different examiners.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
| ZHU, JIANJIAN | 1 | 58.8% | +82.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18519193 | THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS | ABBAS, SYED JARAR | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16968414 | PRESERVATION AND CRYOPRESERVATION MEDIA | ZHU, JIANJIAN | 71d overdue |
| Art Unit | Apps |
|---|---|
| 1674 | 1 |
| 1631 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18519193 | THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS | ABBAS, SYED JARAR | 1674 | §102§112Other | Non-Final OA | — | Pending | Nov 27, 2023 |
| 16968414 | PRESERVATION AND CRYOPRESERVATION MEDIA | ZHU, JIANJIAN | 1631 | §102§103§112DP | Final Rejection | 71d overdue | Pending | Aug 07, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial